Controlled release strategy of paclitaxel by conjugating to matrix metalloproteinases-2 sensitive peptide

Changjiang Huang; Xiulin Yi; Dexin Kong; Ligong Chen; Gong Min

doi:10.18632/oncotarget.10735

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Controlled release strategy of paclitaxel by conjugating to matrix metalloproteinases-2 sensitive peptide

Changjiang Huang, Xiulin Yi, Dexin Kong, Ligong Chen and Gong Min _

PDF | HTML | How to cite

Oncotarget. 2016; 7:52230-52238. https://doi.org/10.18632/oncotarget.10735

Metrics: PDF 2331 views | HTML 2316 views | ?

Abstract

Changjiang Huang1,2, Xiulin Yi2, Dexin Kong3, Ligong Chen1, Gong Min3,4

1School of Chemical Engineering and Technology, Tianjin University, Tianjin, China

2Tianjin Institute of Pharmaceutical Research, Tianjin, China

3School of Pharmacy, Tianjin Medical University, Tianjin, China

4Department of Oncology, University of Oxford, Oxford, UK

Correspondence to:

Gong Min, email: [email protected]

Ligong Chen, email: [email protected]

Keywords: matrix metalloproteinase, tumor targeting peptide, drug conjugate, paclitaxel, tumor metastasis

Received: April 25, 2016 Accepted: May 29, 2016 Published: July 20, 2016

ABSTRACT

Peptide drug conjugates offer a novel strategy to achieve controlled drug release. This approach avoids the clinical obstacles of non-specific toxicity and overall drug resistance of conventional cytotoxic agents, such as paclitaxel. MMP2 plays important functions in tumour proliferation and metastasis. Herein, we conjugated the paclitaxel with a hexapeptide which is specific recognized by MMP2 protein. The conjugate is dissociated upon the MMP2 specific proteolysis at COOH terminal of hexapeptide, PVGLIG.

The results clearly indicated that the PVGLIG-paclitaxel conjugate significantly enhanced the tumor specificity against HT-1080 and U87-MG tumour cells. Our finding suggested that the hexapeptide PVGLIG is capable to act as a controlled and sustained drug carrier of paclitaxel for the treatment against tumour proliferation and metastasis with high MMP2 expression.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10735

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Controlled release strategy of paclitaxel by conjugating to matrix metalloproteinases-2 sensitive peptide

Abstract